Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women

Parkinsonism and Related Disorders

Volumn 16, Issue 6, 2010, Pages 370-375

  Palacios, N ^a   Weisskopf, M ^a   Simon, K ^a   Gao, X ^b   Schwarzschild, M ^c   Ascherio, A ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Caffeine; Epidemiology; Estrogen; Parkinson's disease (PD); Polymorphism

Indexed keywords

ACYLTRANSFERASE; CAFFEINE; CYTOCHROME P450 1A2; DNA; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA;

ADULT; ALLELE; ARTICLE; BLOOD SMEAR; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HAPLOTYPE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL BIOPSY; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

CAFFEINE; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A2; ESTROGEN REPLACEMENT THERAPY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ESTROGEN; RISK FACTORS; SEX DISTRIBUTION;

EID: 77953613164     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2010.02.012     Document Type: Article

References (31)

1. Ross G.W., Abbott R.D., Petrovitch H., Morens D.M., Grandinetti A., Tung K.H., et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000 May 24-31, 283(20):2674-2679.
2. Ascherio A., Zhang S.M., Hernán M.A., Kawachi I., Colditz G.A., Speizer F.E., et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001, 50(1):56-63.
3. Benedetti M.D., Bower J.H., Maraganore D.M., McDonnell S.K., Peterson B.J., Ahlskog J.E., et al. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology 2000, 55(9):1350-1358.
4. Ascherio A., Weisskopf M.G., O'Reilly E.J., McCullough M.L., Calle E.E., Rodriguez C., et al. Coffee consumption, gender, and Parkinson's disease mortality in the Cancer Prevention Study-II cohort: the modifying effects of estrogen. Am J Epidemiol 2004, 160(10):977-984.
5. Schwarzschild M.A., Xu K., Oztas E., Petzer J.P., Castagnoli K., Castagnoli N., et al. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology 2003 Dec 9, 61(11 Suppl. 6):S55-S61.
6. Hong C.C., Tang B.K., Hammond G.L., Tritchler D., Yaffe M., Boyd N.F. Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res 2004, 6(4):R352-R365.
7. Sachse C., Brockmoller J., Bauer S., Roots I. Functional significance of a C>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999, 47(4):445-449.
8. Blum M., Demierre A., Grant D.M., Heim M., Meyer U.A. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A June 15, 1991, 88(12):5237-5241.
9. Chan D.K., Lam M.K., Wong R., Hung W.T., Wilcken D.E. Strong association between N-acetyltransferase 2 genotype and PD in Hong Kong Chinese. Neurology 2003 Mar 25, 60(6):1002-1005.
10. Xu K., Xu Y., Brown-Jermyn D., Chen J.F., Ascherio A., Dluzen D.E., et al. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 2006 Jan 11, 26(2):535-541.
11. Imamov O., Shim G.-J., Warner M., Gustafsson J. Aring, ke. Minireview. Estrogen Receptor beta in health and disease1. Biology of Reproduction November 01, 2005, 73(5):866-871.
12. Ioannidis J.P., Ralston S.H., Bennett S.T., Brandi M.L., Grinberg D., Karassa F.B., et al. Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA 2004 Nov 3, 292(17):2105-2114.
13. Maraganore D.M., Farrer M.J., McDonnell S.K., Elbaz A., Schaid D.J., Hardy J.A., et al. Case-control study of estrogen receptor gene polymorphisms in Parkinson's disease. Mov Disord 2002 May, 17(3):509-512.
14. Hughes A.J., Daniel S.E., Lees A.J. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001, 57(8):1497-1499.
15. Willett W.C., Stampfer M.J., Manson J.E., Colditz G.A., Rosner B.A., Speizer F.E., et al. Coffee consumption and coronary heart disease in women. A ten-year follow-up. JAMA 1996, 275:458-462.
16. Salvini S., Hunter D.J., Sampson L., Stampfer M.J., Colditz G.A., Rosner B., et al. Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption. Int J Epidemiol 1989 Dec, 18(4):858-867.
17. Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J.E., Stampfer M.J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995, 332(24):1589-1593.
18. Hankinson Susan E., Colditz G.A., Hunter D.J., Willett W.C., Stampfer M.J., Rosner B., et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 1995, 76(2):284-290.
19. Lurie G., Maskarinec G., Kaaks R., Stanczyk F.Z., Le Marchand L. Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev June 1, 2005, 14(6):1521-1527.
20. Butler M.A., Iwasaki M., Guengerich F.P., Kadlubar F.F. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci U S A 1989 Oct, 86(20):7696-7700.
21. Yang R., Puranam R.S., Butler L.S., Qian W.H., He X.P., Moyer M.B., et al. Autoimmunity to munc-18 in Rasmussen's encephalitis. Neuron 2000 Nov, 28(2):375-383.
22. Coleman T., Ellis S.W., Martin I.J., Lennard M.S., Tucker G.T. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4-implications for susceptibility to Parkinson's disease. J Pharmacol Exp Ther 1996, 277(2):685-690.
23. Cornelis M.C., El-Sohemy A., Kabagambe E.K., Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006 Mar 8, 295(10):1135-1141.
24. Tan E.K., Chua E., Fook-Chong S.M., Teo Y.Y., Yuen Y., Tan L., et al. Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers. Pharmacogenet Genom 2007 Nov, 17(11):1001-1005.
25. Forsyth J.T., Grunewald R.A., Rostami-Hodjegan A., Lennard M.S., Sagar H.J., Tucker G.T. Parkinson's disease and CYP1A2 activity. Br J Clin Pharmacol 2000, 50(4):303-309.
26. Bandmann O., Vaughan J., Holmans P., Marsden C.D., Wood N.W. Association of slow acetylator geotype for N-acetyltransferase 2 with familial Parkinson's disease. The Lancet 1997, 350:1136-1139.
27. van der Walt J.M., Martin E.R., Scott W.K., Zhang F., Nance M.A., Watts R.L., et al. Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. Neurology 2003 Apr 8, 60(7):1189-1191.
28. Rexrode K.M., Ridker P.M., Hegener H.H., Buring J.E., Manson J.E., Zee R.Y.L. Polymorphisms and haplotypes of the estrogen receptor-{beta} gene (ESR2) and cardiovascular disease in men and women. Clin Chem October 1, 2007, 53(10):1749-1756.
29. Duan J., Wainwright M.S., Comeron J.M., Saitou N., Sanders A.R., Gelernter J., et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet. February 1, 2003, 12(3):205-216.
30. Sowers M.R., Wilson A.L., Karvonen-Gutierrez C.A., Kardia S.R. Sex steroid hormone pathway genes and health-related measures in women of 4 races/ethnicities: the Study of Women's Health Across the Nation (SWAN). Am J Med 2006 Sep, 119(9 Suppl. 1):S103-S110.
31. Ascherio A., Chen H., Schwarzschild M.A., Zhang S.M., Colditz G.A., Speizer F.E. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 2003 Mar 11, 60(5):790-795.